NewAmsterdam Pharma Company NAMS Proceeds From Warrant Exercises
Proceeds From Warrant Exercises at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's proceeds from warrant exercises.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's proceeds from warrant exercises?
- NewAmsterdam Pharma Company (NAMS) reported proceeds from warrant exercises of $651K in Q1 2026.
- How has NewAmsterdam Pharma Company's proceeds from warrant exercises changed year-over-year?
- NewAmsterdam Pharma Company's proceeds from warrant exercises increased by 255.7% year-over-year, from $183K to $651K.
- What is the long-term trend for NewAmsterdam Pharma Company's proceeds from warrant exercises?
- Over 2 years (2023 to 2025), NewAmsterdam Pharma Company's proceeds from warrant exercises has grown at a -56.4% compound annual growth rate (CAGR), from $8.62M to $1.64M.
- What does proceeds from warrant exercises mean?
- This represents the cash inflows received by the company when holders of warrants exercise their rights to purchase shares at a predetermined price. It serves as a source of non-dilutive or equity-linked capital that strengthens the company's cash position. Investors monitor this to understand the impact of equity-linked instruments on the company's capital structure.